BioAtla Garners $45,000,000 New Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    11011 Torreyana Road San Diego, CA 92121 USA
  • Company Description
    BioAtla uses deep expertise in protein and antibody engineering and proprietary technologies to solve critical protein development challenges and produce novel, IP-protectable products for our partners and our own product portfolio.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Through the program funding, Global BIO will share in the risks and the potential returns of BioAtla’s first four CAB candidates that receive Investigational New Drug (IND) approval by the U.S. Food and Drug Administration.
  • M&A Terms
  • Venture Investor
    Global BIO Impact Fund

Trending on Xconomy